Single and two-dose typhoid conjugate vaccine safety and immunogenicity in HIV-exposed uninfected and HIV-unexposed uninfected Malawian children

Autor: Nginache Nampota-Nkomba, Osward M. Nyirenda, Victoria Mapemba, Rhoda Masonga, Priyanka D. Patel, Theresa Misiri, Felistas Mwakiseghile, Richard Wachepa, John M. Ndaferankhande, Bright Lipenga, Pratiksha Patel, Happy Banda, Jennifer Oshinsky, Marcela F. Pasetti, Robert S. Heyderman, Leslie P. Jamka, Divya Hosangadi, Shrimati Datta, Melita A. Gordon, Kathleen M. Neuzil, Matthew B. Laurens
Jazyk: angličtina
Rok vydání: 2024
Předmět:
Zdroj: Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
Druh dokumentu: article
ISSN: 21645515
2164-554X
2164-5515
DOI: 10.1080/21645515.2024.2384760
Popis: Vaccine safety and immunogenicity data in human immunodeficiency virus (HIV)-exposed uninfected (HEU) children are important for decision-making in HIV and typhoid co-endemic countries. In an open-label study, we recruited Malawian HEU and HIV unexposed uninfected (HUU) infants aged 9 – 11 months. HEU participants were randomized to receive Vi-tetanus toxoid conjugate vaccine (Vi-TT) at 9 months, Vi-TT at 15 months, or Vi-TT at 9 and 15 months. HUU participants received Vi-TT at 9 and 15 months. Safety outcomes included solicited and unsolicited adverse events (AE) and serious AEs (SAEs) within 7 days, 28 days, and 6 months of vaccination, respectively. Serum was collected before and at day 28 after each vaccination to measure anti-Vi IgG antibodies by enzyme-linked immunosorbent assay (ELISA). Cohort 1 (66 participants) enrollment began 02 December 2019, and follow-up was terminated before completion due to the COVID-19 pandemic. Cohort 2 (100 participants) enrollment began 25 March 2020. Solicited AEs were mostly mild, with no significant differences between HEU and HUU participants or one- and two-dose groups. All six SAEs were unrelated to vaccination. Anti-Vi geometric mean titers (GMT) increased significantly from 4.1 to 4.6 ELISA units (EU)/mL at baseline to 2572.0 – 4117.6 EU/mL on day 28 post-vaccination, and similarly between HEU and HUU participants for both one- and two-dose schedules. All participants seroconverted (>4-fold increase in GMT) by the final study visit. Our findings of comparable safety and immunogenicity of Vi-TT in HUU and HEU children support country introductions with single-dose Vi-TT in HIV-endemic countries.
Databáze: Directory of Open Access Journals
Externí odkaz: